세계의 인실리코 Drug Discovery 시장

Global In-Silico Drug Discovery Market to Reach US$6.0 Billion by 2030

The global market for In-Silico Drug Discovery estimated at US$3.3 Billion in the year 2024, is expected to reach US$6.0 Billion by 2030, growing at a CAGR of 10.3% over the analysis period 2024-2030. Software as a Service, one of the segments analyzed in the report, is expected to record a 11.2% CAGR and reach US$3.6 Billion by the end of the analysis period. Growth in the Consultancy as a Service segment is estimated at 9.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$871.6 Million While China is Forecast to Grow at 9.9% CAGR

The In-Silico Drug Discovery market in the U.S. is estimated at US$871.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$945.7 Million by the year 2030 trailing a CAGR of 9.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.5% and 8.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.2% CAGR.

Global In-Silico Drug Discovery Market - Key Trends & Drivers Summarized

Why Is In-Silico Drug Discovery Revolutionizing Pharmaceutical R&D Pipelines?

In-silico drug discovery refers to the use of computational modeling and simulation technologies to identify, optimize, and validate drug candidates before physical experimentation. This approach is fundamentally transforming traditional drug development by enabling faster hypothesis generation, target validation, lead compound screening, and toxicity prediction-all within a virtual environment. In contrast to conventional wet-lab methods, in-silico techniques allow researchers to explore vast chemical and biological spaces quickly and cost-effectively, significantly accelerating the early stages of pharmaceutical R&D.

These platforms harness diverse tools such as molecular docking, pharmacophore modeling, quantitative structure-activity relationships (QSAR), and machine learning algorithms to simulate drug-target interactions and predict compound efficacy. With rising R&D costs and high attrition rates in clinical trials, the ability of in-silico methods to de-risk candidate selection and streamline development timelines is driving their growing adoption across biotech firms, academic institutions, and pharmaceutical companies. In-silico approaches also play a critical role in precision medicine and repurposing of existing drugs, further broadening their strategic value in a competitive innovation landscape.

What Technological Advancements Are Expanding the Scope and Accuracy of In-Silico Methods?

The in-silico drug discovery landscape is rapidly evolving with breakthroughs in computational power, algorithmic sophistication, and data integration. Advances in artificial intelligence and deep learning are enabling predictive models with higher accuracy in target identification, compound screening, and ADMET (absorption, distribution, metabolism, excretion, and toxicity) profiling. Neural networks trained on large biochemical datasets can now infer complex structure-function relationships and suggest novel compound structures with enhanced pharmacological properties.

Cloud-based computing and high-performance computing (HPC) platforms are making it possible to perform large-scale molecular simulations, virtual screening, and multi-target optimization in real time. Integration of bioinformatics and chemoinformatics platforms is allowing researchers to analyze multi-omic data-genomics, proteomics, transcriptomics-within in-silico frameworks for more informed target discovery. Additionally, the emergence of digital twins and systems biology models is enabling researchers to simulate disease progression and drug response in silico, offering powerful tools for hypothesis testing and personalized treatment strategies.

Which Therapeutic Areas and Organizations Are Leading Adoption of In-Silico Platforms?

Adoption of in-silico drug discovery is being led by pharmaceutical companies targeting complex and high-cost therapeutic areas such as oncology, neurology, rare diseases, and infectious diseases. These domains benefit significantly from computational approaches due to the high need for precision targeting, biomarker discovery, and mechanism-of-action understanding. In oncology, for instance, in-silico tools are used to design kinase inhibitors or immunotherapies by predicting tumor-specific interactions. In neurodegenerative research, simulations help model the blood-brain barrier and identify CNS-penetrant compounds.

Academic research institutions and biotech startups are also playing a major role in advancing the use of in-silico tools, often through collaborations with software providers and data science companies. Public-private partnerships and consortiums focused on open-source molecular databases and AI-enabled platforms are supporting rapid innovation and technology democratization. Contract research organizations (CROs) are increasingly integrating in-silico services into their drug discovery offerings to meet growing client demand for time-efficient and cost-effective solutions. Furthermore, regulatory bodies are showing increasing openness to simulation-based preclinical data, further legitimizing the role of in-silico approaches in mainstream drug development.

The Growth in the In-Silico Drug Discovery Market Is Driven by Several Factors…

The growth in the in-silico drug discovery market is driven by several factors including escalating drug development costs, increased R&D complexity, and the urgent need for faster innovation cycles. As traditional laboratory and clinical workflows face growing inefficiencies, the pharmaceutical industry is turning to in-silico platforms to accelerate early-stage development, reduce dependency on animal testing, and prioritize candidates with higher success probabilities. The proliferation of biomedical big data, supported by genomic sequencing, electronic health records, and curated compound libraries, is providing the fuel for increasingly accurate and scalable computational models.

Policy and funding initiatives supporting precision medicine and AI integration in healthcare are also catalyzing market growth. The global shift toward data-driven research, especially in response to emerging diseases and public health crises, has underscored the strategic value of simulation tools in rapidly screening and repurposing therapeutics. In tandem, growing investment from venture capital, pharmaceutical alliances, and government programs is supporting platform innovation, start-up development, and talent acquisition. As demand for agile, intelligent, and predictive drug discovery frameworks rises, in-silico methods are expected to become foundational to the future of pharmaceutical innovation.

SCOPE OF STUDY:

The report analyzes the In-Silico Drug Discovery market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Software as a Service, Consultancy as a Service, Software); End-Use (Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 34 Featured) -

• Abzena Ltd.
• Aitia
• Antiverse
• Atomwise, Inc.
• BenevolentAI
• BioNTech SE
• BioSymetrics Inc.
• Certara, USA
• Chemical Computing Group ULC
• Clarivate
• Curia Global Inc.
• Dassault Systemes SE
• DenovAI
• Exscientia
• GenScript
• Iktos
• Insilico Medicine
• Insitro
• Isomorphic Labs
• Ligand Pharmaceuticals

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • In-Silico Drug Discovery - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising R&D Costs and Long Development Timelines Propel Adoption of In-Silico Drug Discovery for Faster, Cost-Efficient Candidate Screening
  • Advancements in AI, Machine Learning, and Deep Learning Algorithms Enhance Predictive Accuracy of Molecular Modeling and Docking
  • Integration of High-Throughput Virtual Screening (HTVS) Accelerates Identification of Promising Drug Candidates at Scale
  • Growth in Cloud Computing and GPU Acceleration Supports Real-Time Simulation and Complex In-Silico Workflows
  • Pharmaceutical Shift Toward Precision and Personalized Medicine Strengthens Business Case for Computationally Driven Drug Design
  • Expansion of Multi-Omics Data Repositories Throws the Spotlight on Data-Driven Insights for Target Validation and Biomarker Discovery
  • Adoption of Digital Twins and Virtual Human Models Enhances Simulation of Drug Efficacy, Toxicity, and Metabolism
  • Increasing Use of In-Silico Tools in Rare Disease and Orphan Drug Development Creates Opportunities in Niche Therapeutic Areas
  • Regulatory Acceptance of In-Silico Evidence for IND and NDA Filings Supports Broader Adoption in Preclinical Research
  • Integration With Laboratory Information Management Systems (LIMS) and ELNs Enables Seamless End-to-End Drug Discovery Pipelines
  • Rising Use of Quantum Computing in Early-Stage Drug Discovery Unlocks Potential for Ultra-Fast Molecular Property Predictions
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World In-Silico Drug Discovery Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for In-Silico Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for In-Silico Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Software as a Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Software as a Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Software as a Service by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Consultancy as a Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Consultancy as a Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Consultancy as a Service by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Software by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Pharmaceuticals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Pharmaceuticals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Pharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • In-Silico Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 26: USA Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: USA 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030
  • TABLE 29: USA Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: USA 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 32: Canada Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Canada Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: Canada 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030
  • TABLE 35: Canada Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: Canada 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• JAPAN
  • In-Silico Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 38: Japan Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Japan Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: Japan 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030
  • TABLE 41: Japan Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Japan Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: Japan 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• CHINA
  • In-Silico Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 44: China Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: China Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: China 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030
  • TABLE 47: China Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: China Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: China 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• EUROPE
  • In-Silico Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 50: Europe Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 51: Europe Historic Review for In-Silico Drug Discovery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Europe 15-Year Perspective for In-Silico Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 53: Europe Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Europe 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030
  • TABLE 56: Europe Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Europe 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• FRANCE
  • In-Silico Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 59: France Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: France Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: France 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030
  • TABLE 62: France Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: France Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: France 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• GERMANY
  • In-Silico Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 65: Germany Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Germany Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Germany 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030
  • TABLE 68: Germany Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Germany Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Germany 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 71: Italy Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Italy Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Italy 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030
  • TABLE 74: Italy Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Italy Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Italy 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • In-Silico Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 77: UK Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: UK Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: UK 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030
  • TABLE 80: UK Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: UK Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: UK 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Rest of Europe Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Rest of Europe 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030
  • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Rest of Europe Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Rest of Europe 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • In-Silico Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Asia-Pacific Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Asia-Pacific 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030
  • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Asia-Pacific Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Asia-Pacific 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF WORLD
  • TABLE 95: Rest of World Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Rest of World Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Rest of World 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030
  • TABLE 98: Rest of World Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Rest of World Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Rest of World 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION